Page last updated: 2024-12-07

inositol 4,5-bisphosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

inositol 4,5-bisphosphate: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID125004
CHEMBL ID21825
CHEBI ID18156
SCHEMBL ID9387601
MeSH IDM0182364

Synonyms (22)

Synonym
1d-myo-inositol 4,5-bis(dihydrogen phosphate)
1d-myo-inositol 4,5-bisphosphate
CHEBI:18156 ,
d-myo-inositol-4,5-bisphosphate
d-myo-inositol 4,5-bisphosphate
C04064
CHEMBL21825 ,
93060-87-8
bdbm50284584
inositol 4,5-bisphosphate
inositol 4,5-biphosphate
inositol-4,5-bisphosphate
myo-inositol, 4,5-bis(dihydrogen phosphate)
myo-inositol 4,5-diphosphate
ins(4,5)p2
gtpl5119
{[(1r,2s,3r,4s,5s,6r)-2,3,4,5-tetrahydroxy-6-(phosphonooxy)cyclohexyl]oxy}phosphonic acid
4,5,-ip2
SCHEMBL9387601
(1r,2r,3s,4r,5s,6s)-3,4,5,6-tetrahydroxycyclohexane-1,2-diyl bis[dihydrogen (phosphate)]
Q27073747
PD048560
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
myo-inositol bisphosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Orexin receptor pathway2915

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Inositol 1,4,5-trisphosphate receptor type 1 Rattus norvegicus (Norway rat)EC50 (µMol)8.63400.00150.41308.6340AID661327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneInositol 1,4,5-trisphosphate receptor type 1 Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID661328Agonist activity at rat IP3R1 expressed in chicken DT40 cells assessed as Ca2+ release relative to control2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
Contribution of phosphates and adenine to the potency of adenophostins at the IP₃ receptor: synthesis of all possible bisphosphates of adenophostin A.
AID661327Agonist activity at rat IP3R1 expressed in chicken DT40 cells assessed as induction of Ca2+ release2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
Contribution of phosphates and adenine to the potency of adenophostins at the IP₃ receptor: synthesis of all possible bisphosphates of adenophostin A.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (32.14)18.2507
2000's7 (25.00)29.6817
2010's12 (42.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.47 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index24.72 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.45%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (96.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]